---
schema_version: "secwatch.filing_event.v1"
accession: "0002019410-26-000005"
form_type: "8-K"
ticker: "CAI"
cik: "0002019410"
company_name: "Caris Life Sciences, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:58:20.908353+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Caris Life Sciences reports preliminary Q4 2025 revenue of ~$281M, up 116% YoY; FY revenue ~$800M, up 94%

## Summary
- Q4 revenue ~$281M (+116% YoY); Molecular Profiling services ~$270M including ~$81M prior-period true-ups.
- Full-year 2025 revenue ~$800M (+94% YoY); Pharma R&D services ~$45M.
- Q4 clinical therapy selection cases ~52,700 (+20%); full-year ~199,300 (+22%).
- Cash, equivalents and marketable securities ~$802M as of Dec 31, 2025, up ~$43M from Sep 30, 2025.
- Company presenting at 44th J.P. Morgan Healthcare Conference today; complete earnings call expected in late Feb 2026.

## SEC filing metadata
- accession: 0002019410-26-000005
- form_type: 8-K
- ticker: CAI
- cik: 0002019410
- company_name: Caris Life Sciences, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2019410/000201941026000005/0002019410-26-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2019410/000201941026000005/cai-20260112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0002019410-26-000005
- JSON: https://secwatch.observer/filing/0002019410-26-000005.json
- Plain text: https://secwatch.observer/filing/0002019410-26-000005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.